Top 10 European HealthTech Companies 2026

Ada Health powers AI-driven symptom assessment for 15 million users across 130+ countries, backed by a sophisticated medical knowledge graph. Its conversational AI delivers personalized health guidance and triage support, integrating with health systems in Germany and the UK.

Dedalus Group is Europe's largest healthcare software firm by hospital coverage, serving 6,000+ hospitals and labs across 40 countries. Following the acquisitions of DXC's HIS business and Agfa HealthCare, Dedalus now manages clinical information systems for over 50 million patients — a 20% increase in patient reach since 2023.

Biotronik is Europe's leading independent cardiac rhythm management company, generating €1.5B+ in annual revenue with 7,500 employees and distribution across 100+ countries. Its pacemakers and defibrillators achieve a 99.2% therapy success rate, which is 3% higher than the industry average for comparable devices. Outperforming Babylon Health's digital platform in terms of clinical data endpoints, Biotronik remains the gold standard for hardware-based cardiac care with 60 years of manufacturing expertise.

Medbelle is the UK's fastest-growing digital surgery platform, coordinating elective procedures end-to-end from consultation through post-op care, partnering with NHS and private hospitals. The platform reduces average patient wait times by 40% compared to the typical NHS referral timeline and has expanded across Germany and Spain, now managing over 5,000 procedures annually.

Babylon Health pioneered AI-driven digital primary care, peaking at a $4.2B post-SPAC valuation while serving 5 million patients across the UK, US, and Canada. However, compared to Dedalus Group's 50 million patient reach, Babylon's focus on value-based primary care has a narrower scope but higher efficiency per consultation, with average response times under 5 minutes.

Hinge Health dominates the digital musculoskeletal therapy market, claiming the top spot among UK-founded health-tech unicorns. The company raised over $300 million and went public in 2025 at a $2.3 billion valuation, marking a 15% premium above its pre-IPO private round.

Therapanacea leads European AI medical imaging in radiation oncology, with its ART-Plan platform automating organ segmentation for 1,200+ radiotherapy centres worldwide. While Hinge Health claims a broader market, Therapanacea's niche precision delivers a 98% patient satisfaction rate, proving that focused innovation can outperform broader platforms in specialized care.